

TRUSTEES' REPORT AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2023

UK MYELOMA SOCIETY

MENZIES
BRIGHTER THINKING

UK MYELOMA SOCIETY

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Notes to the Financial Statements	11 - 19

UK MYELOMA SOCIETY

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2023

Trustees	Dr N Rabin Dr C Bygrave Dr R Hall Dr J Ashcroft Prof G Cook Dr G Pratt Dr M Kaiser Dr K Ramasamy Dr S Stern Dr R Popat Dr M Jenner Dr J Sive S Henshaw Dr S Lawless Dr R Soutar Dr S Lawson A Preston S Castell
Charity registered number	1082702
Principal office	Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield WF1 4DG
Independent examiner	Menzies LLP Chartered Accountants Richmond House Walkern Road Stevenage Herts SG1 3QP
Bankers	Coutts & Co 440 Strand London WC2R 0QS

Trustees' Annual Report for the period

	Period start date				Period end date		
	Day	Month	Year		Day	Month	Year
From	1	April	2022	To	31	March	2023

Section A Reference and administration details

Charity name	UK Myeloma Society		
Other names charity is known by	UKMS		
Registered charity number (if any)	1082702		
Charity's principal address	Dr John Ashcroft, Treasurer Dept of Haematology Pathology building Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield		
	<table style="width: 100%;"> <tr> <td style="width: 70%;">Postcode</td> <td style="width: 30%;">WF1 4DG</td> </tr> </table>	Postcode	WF1 4DG
Postcode	WF1 4DG		

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr Neil Rabin (London)	Chair	January 2021 - November 2023	
2.	Dr Ceri Bygrave (Cardiff)	Wales Representative (Invited Board member) Chair Elect Chair from November 2023	November 2015 -November 2023	
3.	Dr Rachel Hall (Bournemouth)	Board Member/Treasurer	November 2019 -November 2023	
4.	Dr John Ashcroft (Leeds, Mid Yorks)	Past Chair / Teasurer	Past Chair – November 2021- November 2023 Treasurer from November 2023	
5.	Prof Gordon Cook (Leeds)	Past Chair/HTA lead/ College of Myeloma Dean	November 2019- on going	
6.	Dr Guy Pratt (Birmingham)	Secretary	November 2002-November 2023	
7.	Dr Martin Kaiser (London)	Board member	January 2019 – January 2025	
8.	Dr Karthik Ramasamy (Oxford)	Communications Lead	June 2020 - June 2025	

9.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 2020 - November 2024	
10.	Dr Rakesh Popat (London)	Science Lead	November 2018 - November 2024	
11.	Dr Matthew Jenner (Southampton)	Board member	March 2019 - March 2023	
12.	Dr Jonathan Sive (London)	Board member	January 2020 -January 2026	
13.	Sarah Henshaw (Nottingham)	Myeloma Nurse Lead	November 2018 -November 2023.	
14.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2018 -January 2024	
15.	Dr Richard Soutar (Glasgow)	Scotland Representative (Invited Board member)	January 2018 -November 2023	
16.	Dr Shelly Lawson (Sheffield)	Board member	January 2020 – January 2026	
17.	Andrea Preston (Bristol)	Board member Pharmacy lead	November 2021-November 2013	
18.	Sophie Castell (Myeloma UK)	Patient/Charity Representative	January 2018-ongoing	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Menzies LLP	Menzies LLP, Richmond House Walkern road, Stevenage, Herts, SG1 3QP
Bankers	Coutts & Co	440 Strand, London, WC2R 0QS

Name of chief executive or names of senior staff members (Optional information)

--

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association
Trustee selection methods (eg. appointed by, elected by)	Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

- Developing and promoting clinical trials of myeloma treatment and linked scientific studies
- Encouraging collaborative research and innovation in myeloma
- Developing guidelines for the management of patients with myeloma
- Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
- Promoting patient access to treatment through advocacy and working with stakeholders and partners

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMS had a further active year in pursuit of its' charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2022; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue

Revenue received for corporate sponsorship contributed £129,300 (April 2022-March 2023). This re-enforces the support by pharma for the work that the UKMS undertakes.

Education

The Autumn Day was held on 9th November 2023, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was 'Precursor states, gaps in data and resource in myeloma management' and featured Professor Paul G. Richardson from the Dana Farber Cancer Institute, Boston. Prof. Richardson presented the Michael Morley Lecture on 'Practice-changing data from recent trials.

The Spring Day was also a virtual meeting and was held on 23rd March 2023. The theme for this meeting was the, 'Personalised Therapy in Myeloma'. The plenary lecture was given by Professor Morie Gertz from the Mayo Clinic in Rochester. His talk was entitled, 'Diagnosis and therapy of AL amyloidosis in 2023'.

Travel Bursaries

A total of five travel grants for scientific conferences were awarded in 2022 to winning abstracts. Three bursaries of £1,000 each to IMS in Los Angeles in August 2022. The IMS abstracts were presented at the Autumn Day in November 2022. Two bursaries of £1,200 covered the registration fee for ASH (American Society of Haematology Annual Meeting) in San Diego. The ASH abstracts were presented at the Spring Day in March 2023. A conference report written by the bursary recipients from ASH and IMS appeared in the e-newsletter.

Section D

Achievements and performance

Summary of the main achievements of the charity during the year

UKMS rebranding

In November 2022, the UK Myeloma Forum officially rebranded to become the UK Myeloma Society. Following a strategic review, the name change reflected the the growth of the UKMS community. A new logo and website were designed -see www.ukmyelomasociety.org.uk.

Education: The annual meetings

Production of two successful and well attended educational hybrid meetings in November 2022 and March 2023. For full programme details, please refer to the section above and the UKMS website.

Travel Bursaries for scientific meetings

The UKMS in collaboration with the Michael Morley Fund awarded a number of bursaries in 2022-23 to support the attendance of young investigators and specialist nurses at ASH Virtual (American Society of Haematology Meeting) in December 2022. Recipients of the bursaries presented their data at the UKMS Spring Day in March 2023. This is a regular and successful session. For the ASH bursary winners, recipients prepared a short review for the UKMS website and were credited in the UKMS e-newsletter.

Advocacy

The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

Section D

Achievements and performance

The Guidelines group

The UKMS Guidelines Group, Chaired by Dr Simon Stern focused on the management of relapsed myeloma guidelines and the MGUS good practice papers for submission to BSH (British Society of Haematology).

Other guidelines were in various stages of development, notably good practice papers on MGRS and smouldering myeloma. In addition, following discussions at March's Executive meeting, a writing group was formed to produce a good practice paper on imaging in myeloma. The aim was to produce a document that reinforced the importance of functional imaging both at diagnosis and during the later management of myeloma patients.

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group meet virtually twice a year with one face to face meeting planned at the Wellcome Collection on 15th June 22.

Myeloma Nurse Group

The nurse group, Chaired by Sarah Henshaw have worked with MUK reviewing the Nurse Guides that are being reformatted.

Projects for the next 12 months included;

- 1) Self-Administration of bortezomib guidance
- 2) Standardised treatment schedule development - this is a pharmacy group project that the nurse group has supported.
- 3) Working with MUK to set up nurse research plan to do a best practice guide for Peripheral Neuropathy and an audit of the positive aspect that have come out of Covid for nurses in hospitals. The group also worked with Myeloma UK to update and review the nurse guidelines.

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Andrea Preston was newly established in 2021 and launched at the Spring Day in March 2022. The Group will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. See UKMS website for further details.

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2022 fellows : Professor Kwee Yong
Professor Sonja Zweegman
Mr Eric Low OBE

Section E

Financial review

Brief statement of the charity's policy on reserves

The UKMS's policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

Income

Education Grants from Corporate Sponsors contributed approximately £129,300 in March 2022 - April 2023.

A £10,000 charitable contribution was made to the UKMS from the Michael Morley fund in the year 22-23. An additional £5k in 2022 also went to support the website development.

The Michael Morley Fund

This fund is a charitable donation from a patient's estate that is invested on behalf of the UKMS and the interest may be used towards certain projects including supporting two Michael Morley lectures per annum and in 2022 to support the re-branding of the UKMS website.

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants' fees and employer's liability insurance): £32,300.

Spring and Autumn educational meetings in the 22-23 year at approximately £22,515.

- Education Spring Day meeting March 2022 meeting approx £18,000
- UKMRA meeting June 22, Wellcome Collection £1,754
- Website costs £13,000
- Accountants annual fee £2,300

Travel Bursaries 2022

A total of five travel grants for scientific conferences were awarded in 2022 to winning abstracts.

3 x IMS Los Angeles £1,000

2 x ASH San Diego £1,200


Reserves

The UKMF's reserves remain sound as of 31st March 2023 and were £222,697.

Section F Other optional information**Section G Declaration**

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Dr John Ashcroft	
Position (eg Secretary, Chair, etc)	Treasurer	

Date 24-Jan-2024

UK MYELOMA SOCIETY

MENZIES
BRIGHTER THINKING

INDEPENDENT AUDITORS' REPORT TO THE OF UK MYELOMA SOCIETY

Independent Examiner's Report to the Trustees of UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2023.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement


Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 
Stuart Cuzner

Dated: 25-Jan-2024

FCCA ACA

Menzies LLP
Chartered Accountants
Richmond House
Walkern Road
Stevenage
Herts
SG1 3QP

UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2023

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:				
Donations and legacies	3	131,251	131,251	121,320
Investments	4	5,775	5,775	4,285
Total income		137,026	137,026	125,605
Expenditure on:				
Raising funds	5	1,536	1,536	1,633
Charitable activities	6	94,941	94,941	72,984
Total expenditure		96,477	96,477	74,617
Net income before net (losses)/gains on investments		40,549	40,549	50,988
Net (losses)/gains on investments	11	(12,040)	(12,040)	3,863
Net movement in funds		28,509	28,509	54,851
Reconciliation of funds:				
Total funds brought forward		469,680	469,680	414,829
Net movement in funds		28,509	28,509	54,851
Total funds carried forward		498,189	498,189	469,680

The Statement of Financial Activities includes all gains and losses recognised in the year.


The notes on pages 11 to 19 form part of these financial statements.

UK MYELOMA SOCIETY

BALANCE SHEET AS AT 31 MARCH 2023

	Note	2023 £	2022 £
Fixed assets			
Investments	11	191,492	224,717
		<u>191,492</u>	<u>224,717</u>
Current assets			
Debtors	12	2,799	8,199
Cash at bank and in hand		312,278	248,241
		<u>315,077</u>	<u>256,440</u>
Creditors: amounts falling due within one year	13	(8,380)	(11,477)
Net current assets		<u>306,697</u>	<u>244,963</u>
Total assets less current liabilities		<u>498,189</u>	<u>469,680</u>
Net assets excluding pension asset		<u>498,189</u>	<u>469,680</u>
Total net assets		<u><u>498,189</u></u>	<u><u>469,680</u></u>
Charity funds			
Restricted funds		-	-
Unrestricted funds			
Designated funds		275,492	283,717
General funds		222,697	185,963
Total unrestricted funds	14	<u>498,189</u>	<u>469,680</u>
Total funds		<u><u>498,189</u></u>	<u><u>469,680</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

 A7B63086C8D1420.....
Dr J Ashcroft
 (Trustee)

Date: 24-Jan-2024

The notes on pages 11 to 19 form part of these financial statements.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

2. Accounting policies (continued)

2.4 Expenditure (continued)

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

Investments held as fixed assets are shown at cost less provision for impairment.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

3. Income from donations and legacies

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Donations	131,251	131,251	121,320
<i>Total 2022</i>	<i>121,320</i>	<i>121,320</i>	

4. Investment income

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from listed investments	5,351	5,351	4,275
Interest receivable	424	424	10
	5,775	5,775	4,285
<i>Total 2022</i>	<i>4,285</i>	<i>4,285</i>	

5. Raising funds

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Investment management fees	1,536	1,536	1,633
<i>Total 2022</i>	<i>1,633</i>	<i>1,633</i>	

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

6. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2023 £	Total 2023 £	Total 2022 £
Forum expenses	45,907	45,907	34,177
Website costs	13,445	13,445	-
Service charges	3,333	3,333	2,814
Staff costs (see note 9)	29,976	29,976	29,819
Accountancy (see note 8)	2,280	2,280	6,174
	<u>94,941</u>	<u>94,941</u>	<u>72,984</u>
<i>Total 2022</i>	<u>72,984</u>	<u>72,984</u>	

7. Analysis of expenditure by activities

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £	Total funds 2022 £
Forum expenses	45,907	-	45,907	34,177
Website costs	13,445	-	13,445	-
Service charges	3,333	-	3,333	2,814
Staff costs (see note 9)	-	29,976	29,976	29,819
Accountancy (see note 8)	-	2,280	2,280	6,174
	<u>62,685</u>	<u>32,256</u>	<u>94,941</u>	<u>72,984</u>
<i>Total 2022</i>	<u>36,991</u>	<u>35,993</u>	<u>72,984</u>	

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

8. Independent examiner's remuneration

	2023 £	2022 £
Fees payable to the Company independent examiner for the independent examination of the Company's annual accounts	2,280	2,640
Fees payable to the Charity's independent examiner in respect of: Accountancy services for the Charity	-	3,534

9. Staff costs

	2023 £	2022 £
Wages and salaries	29,049	29,151
Pension costs	927	668
	29,976	29,819

The average number of persons employed by the Charity during the year was as follows:

	2023 No.	2022 No.
Administration	1	1

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

10. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 31 March 2023, expenses totalling £933 were reimbursed to 9 Trustees (2022 - £1,919 to 9 Trustees).

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

11. Fixed asset investments

	Listed investments £	Cash portfolio £	Total £
Cost or valuation			
At 1 April 2022	208,723	15,994	224,717
Additions	7,532	(7,532)	-
Disposals	(19,308)	16,672	(2,636)
Revaluations	(9,404)	-	(9,404)
Transfers	-	(25,000)	(25,000)
Management fees	-	(1,536)	(1,536)
Dividend and interest income	-	5,351	5,351
At 31 March 2023	187,543	3,949	191,492
Net book value			
At 31 March 2023	187,543	3,949	191,492
At 31 March 2022	208,723	15,994	224,717

12. Debtors

	2023 £	2022 £
Due within one year		
Other debtors	2,799	2,799
Prepayments and accrued income	-	5,400
	2,799	8,199

13. Creditors: Amounts falling due within one year

	2023 £	2022 £
Trade creditors	6,150	-
Pension fund loan payable	130	-
Other creditors	-	4,428
Accruals and deferred income	2,100	7,049
	8,380	11,477

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

14. Statement of funds

Statement of funds - current year

	Balance at 1 April 2022 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 31 March 2023 £
Designated funds					
Michael Morley Investment Fund	283,717	5,351	(1,536)	(12,040)	275,492
General funds					
General Funds	185,963	131,675	(94,941)	-	222,697
Total Unrestricted funds	469,680	137,026	(96,477)	(12,040)	498,189

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

14. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 April 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Gains/ (Losses) £</i>	<i>Balance at 31 March 2022 £</i>
Designated funds					
Michael Morley Investment Fund	277,212	4,275	(1,633)	3,863	283,717
General funds					
General Funds	137,617	121,330	(72,984)	-	185,963
Total Unrestricted funds	<u>414,829</u>	<u>125,605</u>	<u>(74,617)</u>	<u>3,863</u>	<u>469,680</u>

The designated fund is used to hold the Charity's investments and generate income.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £	Total funds 2023 £
Fixed asset investments	191,492	191,492
Current assets	315,077	315,077
Creditors due within one year	(8,380)	(8,380)
Total	498,189	498,189

Analysis of net assets between funds - prior year

	Unrestricted funds 2022 £	Total funds 2022 £
Fixed asset investments	224,717	224,717
Current assets	256,440	256,440
Creditors due within one year	(11,477)	(11,477)
Total	469,680	469,680

16. Related party transactions

There were no disclosable related party transactions during the year (2022 - none).